TAVABOROLE Drug Patent Profile
✉ Email this page to a colleague
When do Tavaborole patents expire, and what generic alternatives are available?
Tavaborole is a drug marketed by Alembic, Amneal, Chartwell Rx, Cipla, Encube, Lupin Ltd, Padagis Us, Taro, and Zydus Lifesciences. and is included in nine NDAs.
The generic ingredient in TAVABOROLE is tavaborole. There are six drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the tavaborole profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Tavaborole
A generic version of TAVABOROLE was approved as tavaborole by ENCUBE on October 13th, 2020.
Summary for TAVABOROLE
Recent Clinical Trials for TAVABOROLE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Pfizer | Phase 4 |
Pharmacology for TAVABOROLE
Drug Class | Oxaborole Antifungal |
Mechanism of Action | Protein Synthesis Inhibitors |
Anatomical Therapeutic Chemical (ATC) Classes for TAVABOROLE
Paragraph IV (Patent) Challenges for TAVABOROLE
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
KERYDIN | Topical Solution | tavaborole | 5% | 204427 | 13 | 2018-07-09 |
US Patents and Regulatory Information for TAVABOROLE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Alembic | TAVABOROLE | tavaborole | SOLUTION;TOPICAL | 212188-001 | Oct 21, 2020 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
Padagis Us | TAVABOROLE | tavaborole | SOLUTION;TOPICAL | 211848-001 | Oct 13, 2020 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
Cipla | TAVABOROLE | tavaborole | SOLUTION;TOPICAL | 212224-001 | Feb 9, 2021 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
Taro | TAVABOROLE | tavaborole | SOLUTION;TOPICAL | 212215-001 | May 7, 2021 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
Amneal | TAVABOROLE | tavaborole | SOLUTION;TOPICAL | 212256-001 | Nov 25, 2020 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |